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Abstract
Overexpression of HER-2/Neu occurs in about 25–30% of breast cancer patients and is indicative
of poor prognosis. While Her2/Neu overexpression is primarily a result of erbB2 amplification, it
has recently been recognized that erbB2 levels are also regulated on the protein level. However,
factors that regulate Her2/Neu protein stability are less well understood. The prolyl isomerase
Pin1 catalyzes the isomerization of specific pSer/Thr-Pro motifs that have been phosphorylated in
response to mitogenic signaling. We have previously reported that Pin1-catalyzed post-
phosphorylational modification of signal transduction modulates the oncogenic pathways
downstream from c-neu. The goal of this study was to examine the expression of prolyl isomerase
Pin1 in human Her2+ breast cancer, and to study if Pin1 affects the expression of Her2/Neu itself.
Methods: Immunohistochemistry for Her2 and Pin1 were performed on two hundred twenty-
three human breast cancers, with 59% of the specimen from primary cancers and 41% from
metastatic sites. Pin1 inhibition was achieved using siRNA in Her2+ breast cancer cell lines, and its
effects were studied using cell viability assays, immunoblotting and immunofluorescence.
Results: Sixty-four samples (28.7%) stained positive for Her2 (IHC 3+), and 54% (122/223) of all
breast cancers stained positive for Pin1. Of the Her2-positive cancers 40 (62.5%) were also Pin1-
positive, based on strong nuclear or nuclear and cytoplasmic staining. Inhibition of Pin1 via RNAi
resulted in significant suppression of Her2-positive tumor cell growth in BT474, SKBR3 and AU565
cells. Pin1 inhibition greatly increased the sensitivity of Her2-positive breast cancer cells to the
mTOR inhibitor Rapamycin, while it did not increase their sensitivity to Trastuzumab, suggesting
that Pin1 might act on Her2 signaling. We found that Pin1 interacted with the protein complex that
contains ubiquitinated erbB2 and that Pin1 inhibition accelerated erbB2 degradation, which could
be prevented by treatments with the proteasome inhibitor ALLnL.
Conclusion: Pin1 is a novel regulator of erbB2 that modulates the ubiquitin-mediated degradation
of erbB2. The overexpression of Pin1 in a majority of Her2-overexpressing breast cancer may
contribute to maintain erbB2 levels. Pin1 inhibition alone and in conjunction with mTOR inhibition
suppresses the growth of Her2+ breast cancer cells.
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Background
Overexpression of the receptor tyrosine kinase HER-2/
Neu occurs in up to 30% of breast cancer patients and is
indicative of poor prognosis [1]. Her2/Neu plays an
important causal role in breast carcinogenesis, and serves
as a therapeutic target for the humanized monoclonal
antibody Trastuzumab (Herceptin) [2,3]. While Her2-
Neu overexpression is primarily a result of erbB2 amplifi-
cation, it has recently been recognized that erbB2 levels
are also regulated on the protein level [4,5]. However, fac-
tors that regulate Her2/Neu protein stability are less well
understood. The prolyl isomerase Pin1 catalyzes the
isomerization of specific pSer/Thr-Pro motifs that have
been phosphorylated in response to mitogenic signaling.
This post-phosphorylational modification can have pro-
found effects on the stability, function and localization of
the target protein [6,7] Pin1 is overexpressed in a range of
human cancers [8,9], and high Pin1 expression is found in
common adenocarcinomas, such as breast, lung, colon
and prostate cancers [10,11]. In breast cancer, Pin1 levels
are increased more in high grade than in low grade tumors
[8]. A similar trend was found in prostate cancer. Ayala et
al examined Pin1 levels in prostatectomy specimens from
580 prostate cancer patients and found a tight correlation
of high Pin1 levels with poor prognosis [10]. Increased
Pin1 levels were highly predictive of clinical failure, i.e.
the development of metastatic disease in men who had
undergone prostatectomy. In pre-clinical studies, Ryo et
al. showed that siRNA inhibition of Pin1 inhibited both
the growth of prostate cancer cell lines in vitro, and the
outgrowth of prostate cancers in mouse xenotransplant
experiments [12]. The association of Pin1 with an aggres-
sive biology in both prostate and breast cancers points
toward a potential tumor-promoting function of Pin1.
On the molecular level, Pin1-mediated prolyl isomeriza-
tion can regulate its targets by either affecting their tran-
scription, their stability or their function, depending on
its target. Pin1 typically binds phospho-serine or phos-
pho-threonine residues next to Proline. Upon binding
with its WW-domain, Pin1 catalyzes the conversion of the
adjacent prolyl residue from the cis to the trans position
or vice versa. This post-phosphorylational conforma-
tional change can have profound impacts on the function,
subcellular localization or stability of the target protein.
Pin1 modulates several proteins that are activated down-
stream from erbB2, such as the AP1 complex members c-
jun [8] and c-fos and cyclin D1 [13,14]. Pin1 regulates the
phosphorylation status of Raf-1 kinase through regulation
of the interaction with its phosphatase, PP2A. Raf-1 is
responsive to receptor tyrosine kinase activation, and
upon phosphorylation Raf-1 activates MEK and ERK
kinases [15]. Pin1 mediated-prolyl isomerization aug-
ments various molecular functions, such as the transcrip-
tional activity of c-fos [16]or c-jun[8,17], the localization
and stability of cyclinD1[8,14,18-20] or the de-phospho-
rylation of Raf-1[15]. The net result of the diverse effects
of Pin1-mediated prolyl isomerization of these mitotic
phosphoproteins downstream from erbB2 is always accel-
erated progression through mitosis and cell growth.
We therefore hypothesized that inhibition of Pin1 might
block the growth of Her2-positive breast cancer cells. We
have previously shown that Pin1 null mice were largely
protected from breast cancers induced by the c-neu trans-
gene [13]. While 100% of the MMTV-Ras and over 90% of
the MMTV-Neu transgenic mice in the wild-type Pin1
background developed one or several breast cancers
within 75 weeks of observation, over 85% of transgenic
mice in the Pin1 -/- background remained breast cancer-
free over the same period. These in vitro and in vivo data
point toward Pin1 as a potential therapeutic target in ade-
nocarcinomas, and specifically Her2+ breast cancer [13].
However, although these studies showed that the absence
of Pin1 prevented breast cancer induced by Her2 or Ras,
they have not demonstrated that Pin1 inhibition can suc-
cessfully treat breast cancer. Here, we report that Pin1
overexpression is found in 62% of Her2-positive breast
cancer, and that Pin1 inhibition suppresses the growth of
Her2-positive breast cancer cells. While Pin1-inhibition
greatly increased the sensitivity of Her2-positive breast
cancer cells to the mTOR inhibitor Rapamycin, it did not
increase their sensitivity to Trastuzumab. Instead, Pin1-
inhibition interfered with erbB2 signaling by decreasing
erbB2 protein levels through an acceleration of erbB2 deg-
radation.
Materials and methods
Materials
Breast cancer cell lines were purchased from the American
Type Culture Collection (ATCC) and maintained in
DMEM supplemented with 10% fetal bovine serum. Tras-
tuzumab(Genentech, San Francisco) was obtained from
our pharmacy. Rapamycin was from Signal Transduction
Laboratories. Anonymized tissue microarrays with corre-
sponding diagnostic information were purchased from
Immunogenex. Anti-HER2 (Ab-1 and Ab-3) were
obtained from Calbiochem. Actin antibodies and
Cycloheximide were from Sigma. cDNA Synthesis was
done using a reverse transcriptase kit from Roche (Indian-
apolis, IN). Vector control and DN-Pin1 (S16A) mutation
under the control of the CMV promoter have been
described previously [8].
siRNA
Pin1 siRNA duplexes were purchased from and designed
by Qiagen using the HiPerformance Design Algorithm
licensed from Novartis. Additional siRNA duplexes
directed against three other regions of the Pin1 mRNA
were purchased from Invitrogen. All siRNAs led to aMolecular Cancer 2008, 7:91 http://www.molecular-cancer.com/content/7/1/91
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down-regulation of Pin1, the most effective inhibition
was achieved with the target sequence CAG GCC GAG
TGT ACT ACT TCA. A scrambled siRNA was used as a neg-
ative control. HiPerfect Reagent was from Quiagen and
used with Opti-MEM according to manufacturer's instruc-
tions.
Immunoblotting, RNA extraction, and 
immunofluorescence were done as described [13]
Immunofluorescence images were obtained using a Zeiss
Confocal Laser Microscope LSM 510.
Cell viability assay
The Promega Cell-Titer Blue Viability Assay was used to
assess cell viability at the indicated time points. Cells were
grown in 96-well plates and the assay performed accord-
ing to the manufacturer's instructions. Absorption was
read in a Perkin Elmer spectrophotometer with plate
reader.
Immunohistochemistry
Her2/neu-positive human breast cancer tissue and control
slides were obtained from Zymed Laboratories (S. San
Francisco, CA). Additional slides and tissue were also pur-
chased from Tissue Array Networks. The HercepTest from
DakoCytomation was used to stain for Her2, per the
included protocol. Scoring was done blinded by a pathol-
ogist (BW).
Results
Pin1 is overexpressed in 62% of Her2-amplified breast 
cancer
As a first step, we set out to examine the frequency of Pin1
overexpression in Her2+ human breast cancer. A total of
223 breast cancer specimens, mostly from primary
tumors, were analyzed by immunohistochemistry for
Her2 and Pin1 expression. The intensity and distribution
of the stain were graded (Tab 1). Fig. 1 provides examples
of the IHC stains for Her2 (upper panels) and Pin1 (lower
panels). Both stains were specific for the epithelial cancer
cells with little or no no background stain in the architec-
tural and connective tissue portions of the specimen. Cells
were considered Her2-positive (3+) when a strong stain
encircled the entire cell. Weak and incomplete staining
were graded 1+ or 2+ and absent staining 0. Her2 1+, 2+
and 0 were considered negative. Pin1 staining was also
graded according to intensity (0 – 3+). In most cancers we
found nuclear and cytoplasmic localization of Pin1; how-
ever, in some cancers we saw only nuclear staining. Pin1
has been found in both nucleus and cytoplasm in cancer
cells [8,10,21], and it is at this point unclear what biolog-
ical significance a variation in the subcellular distribution
of Pin1 may have. We found that 54% of all breast cancers
Examples of immunohistochemistry stains for Pin1 and Her2 on 3 individual tumors (in rows A through F), IHC for Her2 (A, B,  C) and Pin1 (D, E, F) performed using standard procedures on consecutive slides Figure 1
Examples of immunohistochemistry stains for Pin1 and Her2 on 3 individual tumors (in rows A through F), IHC for Her2 (A, B, 
C) and Pin1 (D, E, F) performed using standard procedures on consecutive slides.Molecular Cancer 2008, 7:91 http://www.molecular-cancer.com/content/7/1/91
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were Pin1-positive (Tab. 1). 28.7% of the breast cancers
were Her2-positive, which is consistent with literature
reports ([22-24]), and amongst the samples that were
Her2-positive in our cohort, 62.5% were also Pin1+. In
summary, a majority of breast cancers overexpressed Pin1
(54%), and Pin1 overexpression was more prevalent in
Her2-overexpressing tumors (62.5%) than in Her2-nega-
tive breast cancers. (Tab. 1). This observation led us to the
question whether Pin1 inhibition would affect the growth
of Her2+ breast cancer cells.
Pin1 inhibition suppresses the growth of Her2+ breast 
cancer cells
The expectation that Pin1 inhibition might suppress the
growth of Her2+ breast cancer cells is based on the follow-
ing pre-clinical observations: 1. Pin1 -/- mice are largely
protected from breast cancers induced by the c-neu trans-
gene [13]. 2. Pin1 is a pivotal regulator of cyclin D1
expression [7,8,13,14,25], and disruption of the cyclin D1
gene in mice also suppresses the ability of the c-Neu trans-
gene to induce tumor development in the mammary
gland [26]. 3. Pin1 inhibition has previously been shown
to inhibit MAPKinase signaling [27] and signaling down-
stream from Raf-kinase [15].
To inhibit Pin1, we optimized Pin1-specific siRNA trans-
fection with a 20-mer directed against the 5' portion of
Pin1 and achieved near-complete ablation of Pin1 in all
breast cancer cell lines examined within 72 hours of trans-
fection (Fig. 2, 3, 4A, B and Fig. 5).
To examine the effect of Pin1 inhibition on the growth
pattern of breast cancer with Her2-amplification, we used
siRNA inhibition of Pin1 in the Her2-positive cell lines
AU565, BT474 and SKBr3. We plated these cells on day 3
after transfection at equal densities. After 4 more days, via-
bility was assessed using the MTT assay, continued Pin1
inhibition was confirmed with immunoblotting. Consist-
ent with prior reports, Pin1 inhibition slowed down cell
growth considerably (Fig. 2). Within 4 days in culture,
control-transfected cells grew exponentially, while the
Pin1 si-RNA treated cells grew very slowly (Fig. 2). In sum-
mary, Pin1-inhibition led to a consistent inhibition of cell
growth in all three Her2-positive cell lines examined.
Pin1 inhibition enhances the growth-inhibitory effects of 
Rapamycin but not of Trastuzumab
Resistance to erbB2-directed cancer treatments is an
unsolved clinical problem [28,29], and therefore we asked
if Pin1 inhibition could enhance the efficacy of other sig-
naling inhibitors that target erbB2-dependent pathways.
The monoclonal antibody Trastuzumab is FDA-approved
for the treatment of breast cancer and inhibits the
homodimerization of ErbB2 [28,30]. Rapamycin and its
analogs, which are currently in late-stage clinical trials in
breast cancer, inhibit mTOR kinase, a key regulator of cyc-
lin D1 [31,32]. Both Trastuzumab and Rapamycin are
clearly effective inhibitors of ErbB2-mediated signaling;
however, they do not block breast cancer cell growth in
vitro [29,33] or in vivo [30] completely but rather attenuate
cancer cell growth. We therefore asked if Pin1 inhibition
could augment the efficacy of these drugs in vitro. We
transfected AU565, BT474 and SKBr3 cells with control or
Pin1 siRNA, and after 3 days we seeded them out at equal
densities and treated these cells with Trastuzumab and
Rapamycin. After 4–7 more days, cell viability was
assessed using the MTT assay, and the data were normal-
ized to controls (vehicle-treated only). We found that the
Her2+ cell lines AU565, BT474 and SKBR3 were modestly
responsive to therapeutic doses of Trastuzumab in vitro at
a range of 1–10 mcg/ml that correspond to therapeutic
trough levels [34]. Unexpectedly, Pin1-inhibition did not
increase the sensitivity of any of the Her2+ cell lines to
Trastuzumab (Fig. 3A, B, C). Recently, concurrent Her2-
directed and mTOR-directed treatments have been pro-
posed to overcome Trastuzumab sensitivity [35]. As
reported earlier [36], the Her2+ cell lines were also sensi-
tive to Rapamycin in the range of 1–10 nM. In contrast to
Trastuzumab sensitivity, Rapamycin sensitivity increased
substantially after Pin1 inhibition (Fig. 3D, E, F), render-
ing the cells sensitive to doses as low as 0.1 nM of the
mTOR inhibitor. In summary, we found that Pin1-inhibi-
tion sensitized Her2-positive breast cancer cells to the
mTOR-inhibitor Rapamycin, but not to the direct erbB2
inhibitor Trastuzumab.
Pin1 inhibition decreases erbB2 levels
We then asked if Pin1 affected components of the erbB2
signaling cascade other than cyclinD1, starting with erbB2
itself. Surprisingly, we found that Pin1-inhibition led to a
decrease in erbB2 levels in all three Her2-positive cell lines
starting 72 hours after Pin1 inhibition (Fig. 4 and 5).
Immunoblotting showed near-complete ablation of Pin1
after 72 hours (Fig. 4A, B, Fig. 5), with concomitant
Table 1: Correlation of Pin1 and Her2 stains in breast cancer. 64/
223 (28.7%) of samples were Her2-positive (3+ index). 122/223 
(54%) were Pin1 + (3+ index), 40/64 (62.5%) of Her2+ breast 
cancer were also Pin1+.
Her - Her2 1+ Her2 2+ Her2 3+ (pos)
Pin1 - 43 9 10 21 83
1+ 0 101 2
2+ 8 422 1 6
3+ (pos) 63 13 6 40 122
114 27 18 64 223Molecular Cancer 2008, 7:91 http://www.molecular-cancer.com/content/7/1/91
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Pin1 depletion inhibits the growth of Her2+ breast cancer cell lines Figure 2
Pin1 depletion inhibits the growth of Her2+ breast cancer cell lines. Cells were transfected with control RNAi (black bars) or 
Pin1 siRNA (grey bars), and seeded on day 3 after transfection at 5000 cells/well in 96-well plates. Cells were allowed to grow 
and the resulting cultures were subjected to an MTT-based viability assay and read in a 96 well reader after 7 days (A) or at the 
indicated time points (B). Assays were done in triplicates.Molecular Cancer 2008, 7:91 http://www.molecular-cancer.com/content/7/1/91
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decrease in erbB2 levels, while Actin levels stayed unaf-
fected. The effect of Pin1-inhibition on Her2 levels was
not only seen in immunoblots but also on the single-cell
level using immunofluorescence (Fig. 4A). In AU565 and
BT474 cells, the Pin1 stain is a diffuse nuclear and cyto-
plasmic stain (red) while the Her2 stain encircles the cyto-
plasmic membrane (green). After Pin1 inhibition (lower
panel), the Her2 stain is only a scant membrane and cyto-
plasmic stain (Fig. 4A). DAPI stain was used to visualize
the nuclei. To ensure that our findings were not an off-tar-
get effect of the siRNA, we used alternate Pin1 siRNAs as
well as over-expression of a dominant-negative mutant of
Pin1 (Pin1 S16A, [13]), and, using this alternate mecha-
nism to suppress Pin1's function, we saw again a decrease
in erbB2 levels when the Pin1S16A mutant was overex-
pressed (Fig. 4C).
Pin1 inhibition leads to decreased Her2 levels through a 
post-transcriptional mechanism
Her2's function is thought to be regulated primarily
through tyrosine phosphorylation, while Her2 protein
levels are regulated by transcriptional mechanisms [37] as
well as by proteasome-mediated degradation [38,39].
Pin1-mediated prolyl isomerization regulates proteaso-
mal degradation of some of its target proteins, such as the
degradation of c-myc[40] and Cyclin E[41], and preven-
tion of degradation of cyclin D1[14,25]. However, a regu-
latory role of Pin1 for a receptor tyrosine kinase such as
Pin1 depletion sensitizes erbB2-amplified cells to Rapamycin but not to Trastuzumab treatments Figure 3
Pin1 depletion sensitizes erbB2-amplified cells to Rapamycin but not to Trastuzumab treatments. SKBR3 cells (A, D), BT474 
cells (B, E) and AU565 cells (C, F) were transfected with control RNAi (dark symbols) or Pin1 siRNA (open symbols), and 
seeded on day 3 after transfection at 5000 cells/well in 96-well plates, and treated with the indicated concentrations of 
Rapamycin or Trastuzumab. Cells were allowed to grow for 5 days and the resulting cultures were subjected to an MTT-based 
viability assay and read in a 96 well reader. Assays were done in triplicates.Molecular Cancer 2008, 7:91 http://www.molecular-cancer.com/content/7/1/91
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Pin1 inhibition leads to the down-regulation of erbB2 Figure 4
Pin1 inhibition leads to the down-regulation of erbB2. A. Immunofluorescence of BT474 or AU565 cells stained with 
anti-Pin1 (red), anti Her2 (green) and nuclear DAPI stain, and a merged image. Cells were analyzed with a Zeiss Confocal 
Microscope 3 days after transfection of either control or Pin1 siRNA. B, C Immunoblotting of Her2 in cells transfected with 
Pin1 siRNA or control siRNA (B), or dominant-negative Pin1 (S16A mutation) or control vector (C). Actin levels (lower panel) 
remained stable while Pin1 levels decreased in response to siRNA treatment (B, middle panel) or increased after DN Pin1 
expression (C, middle panel). Her2 levels decreased both in response to Pin1 siRNA treatment (B, upper panel) and in 
response to expression of DN Pin1 (C, upper panel). Cells were transfected with either vector or the mutant, and lysates col-
lected for immunoblotting 72 hrs later.Molecular Cancer 2008, 7:91 http://www.molecular-cancer.com/content/7/1/91
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Decreased stability of Her2 after Pin1 inhibition Figure 5
Decreased stability of Her2 after Pin1 inhibition. Her2-positive breast cancer cells (SKBR3) were treated with Pin1 control or 
siRNA for 3 days, and then treated with Cycloheximide at 100 mcg/ml, and lysates were obtained at the indicated time points 
and prepared for immunoblotting (A, B). B The intensity of the bands was quantified using ImageJ software and plotted as time 
versus ratio of Her2/Actin intensity for SKBR3.Molecular Cancer 2008, 7:91 http://www.molecular-cancer.com/content/7/1/91
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erbB2 has thus far not been reported. Therefore, we exam-
ined if Pin1 inhibition affected the stability of erbB2. In
cells treated with control and with Pin1 siRNA inhibition,
we followed erbB2 levels after inhibition of protein bio-
synthesis with Cycloheximide (Fig. 5A, B). As reported
earlier [38], erbB2 levels in breast cancer cells treated with
Cycloheximide started to decrease within 3 to 6 hours of
Cycloheximide treatment, and continued to drop after 9
hours [38]. ErbB2 levels before Cycloheximide treatment
were already lowered because of Pin1 siRNA treatment in
SKBR3 (Fig. 5A) and AU565 and BT474 (not shown).
However, in Pin1 siRNA-treated SKBR3 cells where erbB2
ErbB2 degradation induced by Pin1 inhibition can be rescued by proteasome inhibition Figure 6
ErbB2 degradation induced by Pin1 inhibition can be rescued by proteasome inhibition. A. SKBR3 cells were transfected with 
control or Pin1 siRNA for 72 hours. 6 hours prior to protein lysis cells were treated with 100 μM ALLnL. B. Cell lysates were 
immunoprecipitated with anti-erbB2 antibodies and immunoblotting was done using antibodies against erbB2, Ubiquitin, Tubu-
lin and Pin1. C. SKBR3, AU565 and BT474 were transfected with control or Pin1 siRNA for 72 hours. RNA was extracted 
using Trizol reagent and RT-PCR was performed using erbB2 and GAPDH specific primers.
AU565 BT474 SKBR3
c     si c       si c     si
600 kb
100 kb
GAPDH
Her2
Ubiquitin
Tubulin
Pin1
Her2
AB
C
c   si  c   si
ALLnL:  -  -  +    +
input
c   si  c   si c   si  c   si
ALLnL:  -  -  +   + - - +   +
IgG  -Her2
Ubiquitin
Pin1
Her2
IP:Molecular Cancer 2008, 7:91 http://www.molecular-cancer.com/content/7/1/91
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was still detectable after Pin1 siRNA treatment, (Fig. 5A,
B), erbB2 levels decreased precipitously within 3 hours
after Cycloheximide treatment, indicating an accelerated
degradation of erbB2 in the absence of Pin1.
To determine how Pin1 depletion accelerated erbB2 deg-
radation, we examined the ubiquitination of erbB2. We
used the proteasome inhibitor ALLnL to stabilize ubiqui-
tinated erbB2 for 6 hours prior to lysis of the cells. As
expected, the levels of erbB2 and of ubiquitination
increased substantially after treatment with the proteas-
ome inhibitor (Fig. 6A). In co-immunoprecipitation with
erbB2 antibodies we found that the increase in erbB2 is
indeed accompanied by an increase in erbB2 ubiquitina-
tion (Fig. 6B). Interestingly, we found that ALLnL treat-
ment prevented the ubiquitin-mediated degradation of
erbB2 induced by Pin1 depletion (Fig. 6), and that Pin1
itself co-precipitated with the protein complexes that con-
tain ubiquitinated erbB2 (Fig. 6B). Finally, we asked if
Pin1 inhibition affected erbB2 mRNA levels (Fig. 6C). We
used a semi-quantitative RT-PCR approach, and found
that erbB2 transcription did not differ in control and Pin1
siRNA-treated cells. In summary, our data suggest that
Pin1 regulates erbB2 stability by interfering with its pro-
teasomal degradation.
Discussion
Her2-positive breast cancer presents a special clinical
problem as the amplification of Her2 on the one hand is
a clear indicator of poor prognosis, while on the other
hand it is also a clear predictor of response to Her2-
directed therapies [42]. The humanized monoclonal anti-
body trastuzumab (Herceptin) is initially clearly effective
as mono- and in combination treatments. However,
almost all patients develop resistance and the disease
eventually progresses on trastuzumab [42], making the
development of strategies to overcome Trastuzumab
resistance urgent. To evaluate Pin1 as a potential treat-
ment target for Her2+ breast cancer, we set out first to
examine the prevalence of Pin1 expression in Her2-posi-
tive breast cancer, and found co-expression in 62% of
Her2+ breast cancer specimen, suggesting that simultane-
ous inhibition of Pin1 and Her2 might be effective (Fig. 1,
Tab 1). Consistently, all three Her2+ cell lines that we
examined, were strongly inhibited in their growth by Pin1
inhibition (Fig. 2).
We had previously shown that Pin1 -/- mice are largely
protected from the tumorigenic effects of oncogenic c-Neu
or v-Ha-Ras, but not c-Myc [13], as is the case for cyclin D1
null mice [26], and that Pin1 ablation is effective in pre-
venting oncogenic Neu or Ras from inducing cyclin D1 in
mice [13]. These data confirmed the dependence of Her2-
induced tumor growth on cyclin D1 phosphorylation [43]
and the decisive modulatory role that Pin1 plays in the
regulation of this signaling cascade [8,13,14,25]. It is
important to note, however, that in the mouse model, we
showed that Pin1 ablation prevented breast cancer [13],
while in the current experiments we attempted to inhibit
the growth of actual cancer cells. We used Pin1 siRNA
inhibition to down-regulate Pin1 in Her2-positive breast
cancer cells. The down-regulation was achieved within 72
hours, and lasted at least for seven days. Because of these
kinetics, the siRNA inhibition likely mimics a pharmaco-
logical inhibition of Pin1 better than the genetic absence
of Pin1, and our results indicate that siRNA inhibition of
Pin1 is highly effective in inhibiting tumor cell growth of
Her2+ breast cancer cells (Fig. 2).
Recent work on the mechanism of trastuzumab-mediated
growth arrest and on trastuzumab resistance has shown
that in tumors that are trastuzumab-resistant, direct inhi-
bition of one or several of downstream targets of Her2
may help to overcome resistance [44]. The serine/threo-
nine kinase mTOR (mammalian Target of Rapamycin) is
a key integrator of multiple cell stimuli, such as growth
factor and cytokine signals, but also nutrient and energy
status. Furthermore, signals emanating from mTOR regu-
late cell growth, proliferation and survival [31,45]. Inhibi-
tion of the mTOR pathway is effective in inhibiting tumor
growth in cell lines [46] (Fig. 3) and in xenograft models
of erbB2-overexpressing breast cancer [47] and is cur-
rently under investigation in clinical trials. Consistently,
both, Trastuzumab and the mTOR-inhibitor Rapamycin,
inhibited the growth of Her+breast cancer cell lines. Inter-
estingly, we found that simultaneous Pin1 inhibition
increased the sensitivity of these cells to Rapamycin (Fig.
3). The sensitization of Her+ breast cancer cells to
Rapamycin by Pin-inhibition was expected as Pin1 regu-
lates signaling both up- and downstream from mTOR,
thereby likely rendering these cells more vulnerable to
growth arrest as a consequence of Pin1 inhibition. On the
other hand, Pin1 inhibition did not increase the sensitiv-
ity of these cells to Trastuzumab. This may be explained
by our finding that Pin1 induces the degradation of erbB2,
thereby reducing the levels of the Trastuzumab binding
sites (Fig. 4, 5).
Our data indicate that Pin1 is a binding partner of the
erbB2 protein complex, and that erbB2 degradation
induced by Pin1 inhibition can be rescued by proteasome
inhibition (Fig. 6). There is precedent for the interaction
of Pin1 with proteins that subsequently undergo ubiqui-
tin-mediated degradation: The interaction of Pin1 with
p53 protects phosphorylated p53 from interaction with
its ubiquitin ligase, MDM2 [48,49] and Pin1's interaction
with the transcriptional activator Che1 [50], which pro-
motes interaction with HDM2 and subsequent degrada-
tion of Che1. Pin1's exact binding site in the erbB2
protein complex is yet to be determined. The amount ofMolecular Cancer 2008, 7:91 http://www.molecular-cancer.com/content/7/1/91
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Pin1 that co-immunoprecipitated increased substantially
when we prevented proteasome-mediated degradation of
erbB2 that led to the accumulation of ubiquitinated
erbB2. These findings strongly support a role of Pin1 for
the protein stabilization of erbB2. Threonine or Serine
phosphorylation has only recently been found to occur in
erbB2 in response to phorbol-ester or growth factor treat-
ment [51,52]. The effects of threonine or serine phospho-
rylation on the function or stability of ErbB2 are largely
unknown. Two putative phosphorylation sites are flanked
by a proline, and they are therefore potential Pin1 binding
sites, Threonine 701 and Serine 1174. We are currently
investigating if Pin1-mediated prolyl-isomerization at
T701 and/or S1174 could affect the ubiquitination of
erbB2, its kinase activity or its ability to assemble with the
triage complex erbB2-CHIP-HSP90-HSP70 [39]. It is also
possible that Pin1 affects erbB2 stability not through
direct interaction but indirectly through modulation of
the respective Ubiquitin-ligase or some other modifica-
tion of the proteasome complex.
The development of Prolyl-isomerase inhibitors as cancer
therapeutics is still at an early stage. The only inhibitors of
prolyl isomerization currently in clinical trials are the
mTOR inhibitors. These Rapamycin analogs are direct
inhibitors of the prolyl isomerase FKBP12 [31,53], which
then inhibits mTOR, and are in clinical trials in kidney,
breast and lung cancer [47,54]. Pin1 itself has been pro-
posed as a potential therapeutic target, but aside from
Juglone [55,56], specific inhibitors have to date not yet
been identified. Knowing which tumors express Pin1
highly and therefore are "Pin1-inhibitor-sensitive" may
help assess, which tumor types might respond to Pin1-
directed treatments. For therapeutic purposes, the diver-
sity of signaling cascades that Pin1 is involved in may be
an advantage and provide the broad inhibitory coverage
of targets that may be needed to treat cancer efficiently
[57]. Our data suggest that inhibition of phospho-specific
prolylisomerization by Pin1 may provide a way of simul-
taneously blocking multiple signal transduction pathways
and enhancing the efficacy of specific target-directed med-
ications.
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